Human outcomes
Randomised trials or strong population evidence showing fewer deaths, disability or major disease events.
Healthspan before hype
Can a drug slow human ageing?
Dozens of medicines, supplements and molecular targets look interesting. None has yet been proven to make healthy people live longer.
The honest answerBetter control of smoking, blood pressure, cholesterol, diabetes, inactivity, vaccination and cancer screening currently has stronger human evidence than any “longevity stack”.
Read the badge first
One word, five very different levels of evidence
“Anti-ageing” can mean changing a cell marker, improving one disease, extending a mouse’s life, improving human healthspan, or extending human lifespan. Those claims are not interchangeable.
Human clinical signal
Small or early trials showing function, safety or a clinically meaningful endpoint, but not longevity.
Biomarker only
A change in an epigenetic clock, inflammatory marker or biological pathway. Interesting, not validated proof of longer life.
Animal or cell data
Mechanistic evidence or longer life in model organisms. Most candidates never translate successfully to people.
Marketing or anecdote
Testimonials, influencer stacks and uncontrolled self-experiments. A source of hypotheses, not reliable treatment evidence.
The biology
Targets researchers are trying to move
Senescence
Remove senescent cells with senolytics or suppress their inflammatory output with senomorphics.
Nutrient sensing
AMPK, mTOR, insulin/IGF-1 and sirtuin pathways connect energy availability with growth and repair.
Autophagy
Cellular recycling declines with age. Rapamycin and fasting-related signals are studied as possible modulators.
Genome & epigenome
DNA damage, altered gene regulation, telomeres and partial cellular reprogramming are active but high-risk frontiers.
Mitochondria
NAD metabolism, mitophagy and energy production motivate research into precursors, urolithin A and exercise mimetics.
Candidate library
Promising, plausible or simply promoted?
B · disease outcomes
Metformin
AMPK / metabolic signalling
Excellent evidence for type 2 diabetes and its complications; observational longevity signals are confounded. It is not proven to extend life in healthy non-diabetic people.
Watch: GI effects, B12 deficiency, renal function and lactic acidosis risk in specific settings.
B · early human trials
Rapamycin / rapalogs
mTOR inhibition
Robust lifespan extension in several animal models and small human studies of immune or ageing-related endpoints. No proof of longer human life.
Watch: mouth ulcers, infection, lipids, glucose, wound healing and drug interactions.
B · tiny pilot studies
Dasatinib + quercetin
Senolytic combination
A nine-person open-label diabetic kidney disease study reduced several senescence markers after a short course. That is not evidence of extended healthspan or lifespan.
Watch: dasatinib is a cancer drug with potentially serious blood, bleeding, cardiac, pulmonary and interaction risks. Do not self-experiment.
C · biomarkers / trials
Fisetin
Putative senolytic flavonoid
Encouraging animal work; human trials are testing frailty and disease-related outcomes. Supplement doses and purity vary, and clinical benefit remains unproven.
C · mixed human biomarkers
NMN / NR
NAD precursors / sirtuin biology
They can alter NAD-related biomarkers, but consistent improvements in function, disease or lifespan have not been demonstrated.
Watch: long-term safety, product quality and whether boosting NAD is desirable in every tissue or cancer context.
D · mostly preclinical
Resveratrol & sirtuin activators
SIRT1-associated signalling
A famous laboratory story with inconsistent human results, limited bioavailability and no convincing evidence that supplements prolong life.
A · selected indications
GLP-1 medicines
Obesity, diabetes and cardiovascular risk
These drugs reduce weight and, for selected high-risk populations, cardiovascular events. That can improve healthspan, but they are disease treatments rather than proven ageing reversers.
Watch: GI effects, gallbladder disease, pancreatitis concerns, muscle loss and perioperative guidance.
C · early human evidence
Spermidine & urolithin A
Autophagy / mitophagy
Biologically plausible and under active study. Human trials mainly report biomarkers or modest functional endpoints, not longevity.
A · deficiency only
Vitamins & minerals
Correct deficiencies, not ageing
Replacing a true deficiency is valuable. Routine megadoses in well-nourished people rarely extend life and some increase harm.
Watch: excess vitamin A, E, B6, iron and calcium; interactions and false reassurance.
? · indication-dependent
Testosterone, GH, DHEA & “bioidentical” hormones
Hormonal replacement
Appropriate replacement can help a confirmed deficiency. Using hormones to chase youth can cause cardiovascular, clotting, fertility, prostate, liver, glucose and cancer-related harms.
D · experimental
Peptides
Epitalon, GHRPs, BPC-157 and others
Many online products lack approved indications, high-quality human trials, reliable purity or long-term safety data. Mechanistic language is not clinical validation.
D · frontier science
Partial reprogramming & gene therapy
Epigenetic reset / regenerative medicine
Potentially transformative laboratory science, but uncontrolled cell growth, loss of identity and cancer risk make premature commercial treatment especially concerning.
C · biomarker, not lifespan
Telomeres & TA-65
Telomerase activation / astragalus extract
Short blood-cell telomeres correlate with ageing and disease, and some trials report that TA-65 changes average telomere length. A 2025 meta-analysis found no corresponding improvement in frailty or inflammation. Cell mix and assay variability can also create apparent lengthening.
Watch: telomerase is active in most cancers. Longer is not automatically better, and no telomere supplement has proved that it extends human life.
BJ
Case study, not clinical trial
Bryan Johnson and Blueprint
A useful experiment with an unavoidable n=1 problem
Technology entrepreneur Bryan Johnson turned intensive measurement, tightly controlled sleep, diet, exercise, testing and a changing collection of medicines and supplements into the best-known modern longevity self-experiment. It has made preventive health and measurement culturally visible.
What is genuinely useful
Consistency, resistance and aerobic training, sleep discipline, healthy body composition, attention to blood pressure and lipids, transparent measurement, and willingness to stop an intervention that appears unhelpful.
What it cannot establish
There is no untreated Bryan Johnson control. Many variables change together, regression to the mean is unavoidable, and proprietary biological-age scores are surrogate markers rather than proof of a longer or healthier life.
Blueprint also sells products. That does not make every claim false, but it creates a financial conflict that readers should factor into the evidence assessment.
The unglamorous winners
The strongest current longevity programme is mostly familiar
Do not smoke
Stop tobacco; avoid chronic smoke exposure.
Move and build strength
Aerobic fitness, balance and muscle preserve function.
Treat real risk
Blood pressure, LDL cholesterol, diabetes, sleep apnoea and osteoporosis.
Use proven prevention
Vaccination and evidence-based cancer screening appropriate to age and risk.
Protect connection
Sleep, mental health, hearing, vision and social connection all shape healthspan.
Avoid overtesting
More scans and biomarkers can produce false alarms, procedures and harm.
Why equally healthy people age differently
There is no single biological clock
Genes, early-life development, infections, immune history, hormones, environmental exposures, injuries, medications, chance and social conditions all interact with lifestyle. Two people can follow similar routines and still differ in vascular, immune, brain, muscle and cancer ageing.
Phenotypic age
Uses ordinary measurements such as albumin, glucose, inflammation and blood-cell indices to estimate mortality-related risk. Useful for populations; not a diagnosis or countdown clock.
Epigenetic clocks
Patterns of DNA methylation can predict outcomes, but different clocks answer different questions and can disagree. A changed score is not yet proof that an intervention extends life.
What the body can do
Walking speed, grip strength, cardiorespiratory fitness, balance, cognition, hearing and frailty often matter more clinically than a seductive single “age” number.
RealAge and calculators
Michael Roizen popularised translating modifiable risks into years older or younger. It can motivate prevention, but a questionnaire score is an educational risk model, not a literal measurement of tissue age.
The red-wine question
Alcohol is not a longevity treatment
Older observational studies linked moderate drinking, especially red wine, with heart health. Better-controlled evidence has not established cause and effect, while alcohol increases cancer risk and can worsen blood pressure, atrial fibrillation, sleep and liver disease. If you do not drink, do not start for health. Grapes, berries and exercise do not require ethanol.
Measurements worth discussing with a clinician
Blood pressure · smoking · waist and body composition · movement and strength · sleep · social connection · LDL and other lipids · HbA1c/glucose · kidney and liver health · vaccinations · age- and risk-appropriate screening · medication review · hearing, vision and dental health · mental health · alcohol and other substances · hobbies, learning and purpose.
Old genes, long lives
There is no single longevity gene
Human lifespan and healthspan are complex, polygenic traits shaped by thousands of variants interacting with development, infections, environment, behaviour, medical care and chance. A gene can strongly cause one rare disease; most common longevity variants only shift probability.
A large, actionable effect
Familial hypercholesterolaemia is a clear example. Harmful variants involving LDLR, APOB, PCSK9 or LDLRAP1 can produce very high LDL from birth and premature coronary disease. Finding and treating affected families can add healthy years now; no speculative rejuvenation is required.
Nature can reveal a drug target
Some loss-of-function PCSK9 variants lower LDL and heart-disease risk. Understanding that biology helped produce PCSK9-blocking medicines. This is a realistic model for ageing research: discover a protective pathway, then mimic it safely without rewriting every cell.
A clue, not a guarantee
Variants near FOXO3 repeatedly associate with exceptional longevity, while APOE variants influence Alzheimer's and cardiovascular risk. Association does not make a destiny test: effects vary across populations and depend on many other genes and exposures.
LDLR · APOB · PCSK9 · LPA
Lifelong exposure matters. Earlier recognition and control of LDL, lipoprotein(a), blood pressure and smoking can outweigh fascination with a generic “age test”.
APOE and inherited dementias
APOE changes risk, not certainty. Rare variants in genes such as APP, PSEN1 and PSEN2 can cause familial early-onset Alzheimer's disease. Testing has family implications and deserves genetic counselling.
Repair, cancer and senescence
Genome stability, telomeres, tumour suppression and cellular senescence are entangled. Increasing cell survival or replication can theoretically preserve tissue while also enabling cancer; a youthful pathway is not automatically a safe pathway.
FOXO · mTOR · AMPK · IGF
These pathways alter lifespan in laboratory organisms and are targets of intense research. Human systems are less forgiving: suppressing growth, immunity or metabolism enough to affect ageing may introduce infection, healing, muscle or metabolic harms.
Could genes be changed?
Already real for selected diseases, not for ageing
The landmark: Casgevy uses CRISPR/Cas9 to edit a patient's own blood-forming stem cells outside the body so they produce more fetal haemoglobin. It is approved for severe sickle cell disease and transfusion-dependent beta-thalassaemia in eligible patients. This is durable therapeutic genome editing in humans, not a theoretical prospect.
The burden matters: cells must be collected and individually manufactured, then the patient receives intensive myeloablative conditioning before reinfusion. Infection, infertility, delayed blood-cell recovery, off-target edits and possible malignancy require specialist care and long follow-up. A severe single-gene blood disease can justify risks that an otherwise healthy person seeking longevity could not.
Editing inside the body: early trials are testing delivery directly to organs. Investigational base editing of liver PCSK9, for example, aims to produce a durable LDL reduction by mimicking naturally protective variants. Early biological effects do not yet establish lifetime benefit, rare harms or suitability for routine prevention.
Somatic editing changes cells in one treated person. Whole-body ageing would require safe delivery across many tissues, durable control, minimal off-target change and a way to avoid creating cancerous clones.
Germline editing would make heritable changes affecting future generations who cannot consent. It is ethically and legally restricted in many places and would be an extraordinarily poor tool for complex, uncertain longevity traits.
Polygenic scores combine many variants but do not include lifestyle, present disease or every environmental factor. Performance can fall when the reference research poorly represents a person's ancestry. They are risk estimates, not biological-age meters or expiry dates.
The near-term win: find high-impact inherited disease, screen relatives, and use proven prevention or treatment. The future goal is not merely more birthdays, but longer life with cognition, mobility, independence and meaning intact.
Telomeres and division
TERT, TERC, DKC1, TINF2 and related genes maintain telomeres and chromosome ends. Critically short telomeres can stop division, trigger cell death and contribute to marrow failure, pulmonary fibrosis and other telomere-biology disorders. But senescence also restrains damaged cells, and telomerase is exploited by many cancers. “Lengthen every telomere” is not a safe anti-ageing plan.
Senescence and immunity
Senescence can halt a damaged cell and aid wound repair, yet persistent senescent cells can release inflammatory signals and disturb neighbouring tissue. Ageing immunity becomes less effective at clearing them while also responding less reliably to infection and vaccination. Removing the wrong cells, or suppressing immune pathways too broadly, could impair healing, defence or tumour surveillance.
Arteries, heart and fitness
Genes influence lipids, clotting, blood pressure, cardiomyopathy, rhythm and exercise response, but “clean arteries” cannot be read from DNA alone. Measure LDL and other lipids, blood pressure, glucose, smoking exposure, fitness and family history. High-impact findings such as familial hypercholesterolaemia can lead to earlier treatment and cascade testing of relatives.
Brain ageing is not one disease
Late-onset Alzheimer's is usually multifactorial; APOE changes risk but does not determine fate. Rare APP, PSEN1 or PSEN2 variants can cause familial early-onset disease. Most Parkinson's is also complex, though familial forms involve genes including LRRK2, SNCA, PRKN, PINK1 and PARK7. Huntington's is different: a pathogenic HTT expansion is strongly predictive.
Would you want to know?
Test only when the answer has a purpose
Knowledge can guide prevention, treatment, family screening, reproductive decisions, research participation and future planning. It can also create anxiety, alter family relationships and reveal information about relatives who did not ask to know.
More actionable: a strong family pattern of premature heart disease, certain cancers, cardiomyopathy or a recognised inherited syndrome may change surveillance and treatment now.
Risk, not destiny: an APOE result cannot say whether or when someone will develop Alzheimer's. NIH does not recommend routine genetic testing to diagnose or predict late-onset Alzheimer's; strong family history or unusually early symptoms warrant specialist assessment.
Highly predictive, limited prevention: predictive testing for Huntington's can profoundly affect life plans while no treatment currently prevents its progression. Established programmes use pre-test genetic counselling, neurological review and psychological support, and respect the right not to know.
Before ordering: ask what exact variant is being tested, how accurate the laboratory is, what a positive, negative or uncertain result would change, who else might learn the result, and whether insurance or employment protections apply in your jurisdiction. Consumer tests may test only selected variants and need clinical confirmation.
“Dark DNA”
AI may illuminate the genome's control system
More like dark matter than empty space: important effects can be detected before every component or mechanism is understood. Unlike cosmic dark matter, however, the DNA is physically available and increasingly readable. The darkness lies mainly in interpreting what a sequence does in a particular cell, life stage and environment.
A popular umbrella, not one scientific category: “dark DNA” may refer to non-coding regulatory DNA, repetitive or structurally complex regions that older sequencing could not read reliably, variants whose function remains unknown, or sequences missing from an incomplete reference assembly. The precise meaning matters.
“Dark” does not mean useless. Only a small part of DNA directly encodes proteins. Non-coding regions include promoters, enhancers, silencers, structural sequences and instructions for regulatory RNAs. A variant may alter when a gene turns on, in which cell, or how much product it makes without changing the protein itself. Non-coding is not synonymous with “junk”.
What is newly visible: population-scale whole-genome sequencing captures rare non-coding variants, insertions, deletions and structural rearrangements missed by older SNP arrays or exome tests. Long-read and pangenome methods reveal repetitive and structurally complex regions that were previously difficult to map.
Where AI helps: models can integrate DNA sequence with gene expression, proteins, metabolites, imaging, medical records and exceptional-longevity cohorts; predict which of billions of variants may alter regulation; and nominate pathways or drug targets for laboratory testing.
Where AI stops: correlation and prediction are not proof. Survivorship bias, ancestry imbalance, inaccurate records and thousands of interacting variables can produce convincing false leads. A credible longevity finding must replicate across populations, alter biology in the predicted direction and ultimately improve meaningful human outcomes without unacceptable harm.
Epigenetics
Same DNA, different instructions
DNA methylation, histone modifications, chromatin folding and regulatory RNAs help determine which genes a cell can use. They let a neuron and liver cell behave differently despite carrying essentially the same genome, and they change with development, disease, exposure and age.
Clocks: machine-learning models can estimate age or health risk from methylation patterns. Different clocks measure different signals and can disagree. Moving a clock backwards is evidence of a molecular change, not by itself proof of restored function or longer life.
Cause or record: an epigenetic mark may drive decline, compensate for damage, or merely record smoking, inflammation, stress, cell composition or disease. Editing a marker without understanding its role could remove a defence rather than repair a cause.
Partial reprogramming: brief or selective exposure to reprogramming factors has restored some youthful molecular features in cells and improved selected outcomes in animals. It aims to reset age-associated regulation while preserving cell identity.
The central danger: full reprogramming produces pluripotent cells by erasing specialised identity. In a body that can mean loss of tissue function, abnormal growth, dysplasia or tumours. Delivery, dose, timing, reversibility and long-term cancer surveillance are unresolved.
Lifestyle enters here: smoking, exercise, sleep, diet, alcohol, infection, pollution and social adversity can associate with epigenetic patterns. That does not mean a commercial clock can prescribe a personalised longevity programme or that every mark is reversible.
What success would look like: not merely younger methylation, but replicated improvement in organ function, frailty, disease, cognition and survival, with no excess cancer or loss of cellular identity.
Beyond DNA
A cell is a working system, not a genome in a box
Ageing can emerge from failures in information, energy, structure, waste disposal and communication. These systems interact, so repairing one marker may do little if the rest of the network continues to fail.
The working messages
Messenger RNA carries instructions for proteins; microRNAs, long non-coding RNAs, splicing, editing and chemical RNA modifications regulate what is made. Age can alter RNA processing and quality control. RNA is both a therapeutic tool and a transient, context-sensitive readout.
Energy, stress and signals
Mitochondria have their own DNA but depend heavily on nuclear genes. They make cellular energy, shape metabolism, calcium, inflammation and programmed cell death, and must continually fuse, divide and be recycled. Dysfunction is linked with frailty and neurodegeneration, but “boosting mitochondria” is not one defined treatment.
Scaffolds and transport tracks
Microtubules organise cells, separate chromosomes and move cargo. Long neurons depend on them to transport mitochondria, vesicles and proteins over great distances. Tau normally associates with microtubules; abnormal tau and transport failure are central to several neurodegenerative diseases.
Fold, repair or remove
Chaperones fold proteins, proteasomes break down selected proteins, and autophagy with lysosomes clears larger damaged components. With age, misfolded and aggregated proteins can outpace disposal, contributing to cataract, muscle decline and brain disease.
Matrix, vessels and signals
Collagen cross-linking, extracellular matrix stiffness, capillary supply, immune signals and neighbouring cells can make a genetically normal cell behave badly. Rejuvenating isolated cells does not automatically rebuild an aged tissue architecture.
Partner, marker or both?
Microbial communities influence metabolites and immunity and change with diet, medicines, geography, disease and age. Associations with healthy ageing are intriguing, but cause and effect are difficult to separate and commercial microbiome scores remain ahead of proven longevity treatment.
The central trade-off
Some ageing is the price of suppressing cancer
Senescence stops damaged cells dividing. Telomere shortening limits repeated replication. Apoptosis removes cells carrying serious damage. Immune surveillance finds abnormal clones. These defences can also reduce regeneration, exhaust tissues and promote inflammation as organisms age.
A rejuvenation treatment that lengthens telomeres, blocks senescence, suppresses cell death or drives proliferation may help healthy tissue while giving an existing precancerous clone more time and capacity to grow. Older bodies already contain many somatic mutations and small competing clones, even without diagnosed cancer.
The goal cannot be maximum growth. A credible therapy would need cell- and tissue-specific delivery, a controllable dose and duration, preserved tumour suppression, monitoring for clonal expansion and evidence that functional benefit lasts longer than any added cancer risk. The safest strategy may combine repair with stronger detection and elimination of dangerous cells.
Immune ageing
Weaker defence, louder background noise
The ageing immune system is not simply switched down. It becomes less coordinated: slower or less precise against some new infections and abnormal cells, yet prone to persistent low-grade inflammation known as inflammaging.
T cells and the shrinking thymus
The thymus normally trains new T cells but becomes smaller and less active with age. The repertoire of naive T cells able to meet an unfamiliar pathogen narrows, while repeated exposures can leave expanded populations of experienced or exhausted cells. B-cell diversity and antibody quality can also change.
Dendritic cells, macrophages and NK cells
Dendritic cells capture antigens and instruct T cells; macrophages engulf debris and coordinate repair; natural killer cells help remove infected or malignant cells. Age can alter their migration, signalling and antigen presentation. That may weaken vaccine responses and tumour surveillance while sustaining inflammatory signals.
A chronic signal without a useful target
Senescent cells, visceral fat, altered gut barriers, persistent infections, damaged molecules and age-related blood-cell clones may all contribute. Chronic cytokine signalling is associated with frailty and cardiovascular, metabolic and neurodegenerative disease, but suppressing inflammation indiscriminately can impair defence and healing.
Glymphatics, sleep and neuroinflammation
The glymphatic pathway moves cerebrospinal fluid through channels around brain blood vessels and connects with meningeal lymphatic drainage. It appears especially active during sleep and may help clear metabolic waste. Human evidence is growing, but no supplement or commercial “detox” has been shown to flush the brain or prevent dementia through this pathway.
Prepare rather than “boost”
Age- and risk-appropriate vaccination, regular activity, adequate nutrition and protein, restorative sleep, oral health, smoking cessation and control of diabetes and other disease support immune resilience. Older people may need vaccine formulations or schedules designed for weaker responses. Immunocompromised people need individual advice, especially about live vaccines.
Rejuvenate without misfiring
Researchers are studying senolytics, mTOR modulation, improved adjuvants, thymic regeneration, targeted cytokine control and rejuvenation of blood-forming stem cells. Success must mean fewer serious infections, cancers and disability, not merely younger-looking immune markers. Excess activation could cause autoimmunity, tissue injury or rejection; excess suppression could invite infection and cancer.
There is no single validated “immune age”. Cell counts, inflammatory markers and vaccine responses measure different functions. Results depend on recent infection, medicines, frailty and chronic disease, so a commercial panel cannot yet give a definitive biological-age score.
A genuinely recent field: the glymphatic pathway was named from animal work in 2012. Direct proof-of-principle imaging of its channels in living humans was reported only in 2024, in five surgical patients. Its importance in human ageing is still being resolved, so treatment and “brain detox” claims should be treated cautiously.
Healthspan means brainspan
A fit body is not enough if cognition is lost
Dementia can take memory, judgement, communication, personality and independence while the heart, lungs and muscles remain relatively strong. A longevity claim that ignores cognitive function is incomplete.
Strokes matter just as much. One large ischaemic stroke or intracerebral haemorrhage can abruptly remove speech, movement, judgement or independence. Repeated small infarcts and small-vessel disease can accumulate into vascular dementia, and vascular injury commonly coexists with Alzheimer's pathology as mixed dementia.
Find atrial fibrillation. AF can allow clots to form in the heart and travel to the brain, causing a large embolic stroke. It may cause palpitations or breathlessness, but intermittent AF can be silent and missed by a single pulse check or ECG. An irregular pulse, wearable alert or suspicious symptoms need clinical confirmation; longer monitoring may be required. Read more at Atrial Fibrillation Causes.
Exercise, blood-pressure control, not smoking, treating diabetes and high cholesterol, good sleep, social and intellectual activity, and prompt assessment of stroke symptoms all support brain health. Blood pressure is especially important for preventing both ischaemic stroke and brain haemorrhage. For confirmed AF, clinicians estimate clot and bleeding risks and may prescribe an anticoagulant. Aspirin is not an equivalent substitute for preventing most AF-related strokes, and neither aspirin nor an anticoagulant should be started or stopped without individual advice because both can cause serious bleeding. See Blood Thinners Risks for the benefits, interactions and warning signs.
None of these measures guarantees protection: Alzheimer's disease, vascular injury, Lewy body disease, frontotemporal degeneration and mixed pathologies can affect even physically fit people.
The meaningful outcome is not a younger test result. It is more years able to recognise people, make decisions, communicate, move safely, pursue interests and participate in life. Research should measure cognition and daily function alongside survival, frailty and cancer risk.
The search for immortality
Could medicine outrun ageing?
Slowing ageing means accumulating damage more slowly. Rejuvenation would repair enough damage to restore genuinely younger function, rather than merely changing appearance. Regeneration and partial cellular reprogramming make limited reversal biologically conceivable, but no treatment has made an older human body young again.
Longevity escape velocity is the idea that future treatments might add more than one year of remaining healthy life during each year a person survives. A first generation of therapy would buy time to reach a better one, repeatedly.
The arithmetic is coherent; the evidence is not here. Medicine has greatly improved average life expectancy and survival from particular diseases, but the verified human record remains 122 years. Recent demographic work finds radical life extension increasingly difficult under current medicine, while scientists still debate whether there is a fixed absolute ceiling.
What would have to work
Repeated repair across cancer suppression, vascular ageing, immunity, neurodegeneration, metabolism, stem cells, accumulated mutations and tissue architecture, without one intervention worsening another system.
Cryonics
Preservation after legal death is a wager on future repair technology. No cryopreserved human has been revived, and preserving structure is not evidence that memory and personhood can be restored.
Mind uploading
Whole-brain emulation remains theoretical. Even a future digital copy that reproduced memories and behaviour would raise an unresolved question: is it continuity of the original person or a new copy?
Meaning beyond medicine
Not everyone experiences death as a technical problem to defeat. Belief in an afterlife or reincarnation, cultural traditions, family continuity, spirituality and acceptance of mortality can reduce fear and alter the appeal of extreme life extension. Science can test biological claims; it cannot settle metaphysical belief.
The practical bet
Live well enough to benefit from future advances without sacrificing the present to speculative treatments. More healthy years is a defensible goal; “forever” is not a current medical promise.
Cryopreservation in practice
A real service built around an unproved future rescue
How it works: only after legal death, teams cool the body, support circulation where possible, replace blood with cryoprotectant and lower temperature toward liquid-nitrogen storage. Vitrification aims to form a glass-like state with less ice than ordinary freezing; toxicity, incomplete perfusion, cracking and damage during cooling or rewarming remain major barriers.
How common: it is exceptionally rare. Alcor reports more than 1,500 members and over 250 people in care across 28 countries. Other providers add hundreds rather than millions.
Approximate advertised cost: Alcor lists US$80,000 for neuropreservation and US$220,000 for whole-body preservation. Cryonics Institute lists US$28,000–35,000 for members, excluding local help, standby and transport that can add substantially more. Life insurance commonly funds arrangements.
Chance of revival: unknown, not merely “low” in a measurable actuarial sense. Medicine can freeze and revive cells, embryos and some small tissues; it cannot vitrify, store, uniformly rewarm and revive a human brain or body. Future technology would also need to reverse the original fatal disease, post-death oxygen injury and preservation damage while retaining the physical basis of memory.
If revival became possible: storage institutions, funding, legal status, future willingness to revive, identity and social reintegration would still matter. The technology cannot guarantee that an organisation or society will persist for centuries.
Possible science, enormous gaps
Head or body transplantation
There is a real event behind the Frankenstein-like stories. In 1970, Robert White's team connected isolated monkey heads to donor bodies and restored blood flow. Within hours the heads had awake EEG patterns, tracked with their eyes, chewed and swallowed. That was not revival or a successful whole-body transplant: the spinal cords were not reconnected, the animals were paralysed below the neck and survival in the published experiments was only 6-36 hours. No human head transplant has succeeded. Spinal-cord repair, rejection, brain ischaemia, autonomic failure and profound animal-welfare and human-identity questions remain.
Cloning
A clone would share nuclear DNA, much like a delayed identical twin. Different development, experiences and brain wiring would make a new person, not a continuation or backup of the donor's consciousness.
Replacement bodies and organs
Lab-grown organs, xenotransplantation, prosthetics and regenerative medicine are credible routes to replacing failing parts. Building an entire compatible adult body and connecting it to an existing brain is far beyond present capability.
Digital brain or mind upload
Brain-computer interfaces can read limited signals; they do not extract a mind. Uploading would require mapping and reproducing vast dynamic neural and biochemical detail. Even a perfect simulation leaves the identity problem unresolved.
When longer is not automatically better
Medicine changed death. It did not make every extra intervention worthwhile.
Vaccines, sanitation, surgery, intensive care and modern drugs have prevented immense suffering and given many people years of good life. That success, amplified by headlines promising breakthroughs, can also create an expectation that every decline must have another technical rescue and that death represents failure.
Possible is not probable
A treatment that changes cells, helps mice or adds weeks in a selected trial population can become a “cure” in a headline. Near the end of life, understandable hope can make small chances feel like promises. Good consent includes the best case, most likely case and worst case, in ordinary language.
No single modern attitude
For some people an afterlife, reincarnation or spiritual continuity makes death less final. Others find meaning without religion, while some experience non-existence as especially frightening. Secularisation may influence attitudes in some societies, but personal belief, culture, family and experience vary too much for a simple cause-and-effect claim.
Palliative care is active medicine
Relief of pain, breathlessness, anxiety and family distress can begin alongside treatment. It is not “doing nothing”. WHO reports that early palliative care improves quality of life and can reduce unnecessary hospital use, yet only a minority of people who need it receive it.
Plan while choices are still yours
This is not only an old-age document. Dementia may erode capacity gradually, while stroke, traumatic brain injury, severe infection or hypoxic brain injury after cardiac arrest can remove it suddenly at any age. An advance-care plan, substitute decision-maker and honest discussion of unacceptable outcomes can prevent a crisis from defaulting to maximal intervention. A trial of treatment can have a defined stopping point if it is not achieving the patient's goal. Forms, legal effect and terminology vary by location.
Plan at Advance Care DirectiveA good death is not the opposite of good medicine. Sometimes the right goal remains cure or more time. Sometimes it becomes comfort, lucidity, home, reconciliation or avoiding burdens that no longer offer a reasonable benefit. Those values belong to the person, informed by honest clinical advice.
Research, not retail
Look for a registered clinical trial
Trials provide eligibility screening, monitoring and a protocol. Buying prescription medicines or research peptides online is not an equivalent experiment.
Mirror age versus medical age
Looking younger is a different endpoint
Aesthetic treatment can be worthwhile when expectations are realistic. It may improve appearance or confidence, but removing a wrinkle does not rejuvenate arteries, immunity, brain, muscle or metabolism.
Sun protection & retinoids
Daily UV protection reduces photoageing and skin-cancer risk. Retinoids have credible evidence for fine lines, pigmentation and texture, but can irritate skin and require pregnancy precautions.
Botulinum toxin & fillers
Botulinum toxin relaxes selected muscles; fillers replace volume. Results fade. Poor placement can cause asymmetry or functional problems; accidental filler injection into a blood vessel can rarely cause tissue death, blindness or stroke.
Lasers, peels & microneedling
Resurfacing can improve pigment, texture and scars by provoking repair. Burns, pigment change, infection and scarring are possible. FDA has reported serious injuries with some radiofrequency microneedling uses.
Ultrasound, RF & cryolipolysis
Energy or cold devices may tighten tissue or reduce a local fat bulge. Effects vary; burns, nerve symptoms, uneven contour and paradoxical fat growth can occur.
Cosmetic surgery
Facelift, eyelid surgery, liposuction and other operations may produce durable visible change. Anaesthesia, bleeding, clots, infection, nerve injury, scarring and revision surgery must be weighed honestly.
Cosmetic, drug or device?
Moisturising or concealing lines is cosmetic. Claims to increase collagen or change body structure may make a product a drug or device claim. “Cosmeceutical” is marketing language, not an evidence grade.
Bottom line: good skin care can protect skin and procedures can change appearance. Neither should be sold as proof of slower whole-body ageing or longer life. A complication, poor technique or repeated overtreatment can also make someone look less natural or leave asymmetry, scarring, altered expression, abnormal contours or permanent disfigurement. More treatment is not a linear route to looking better.
The question no procedure can settle
Will looking younger make you happier?
Sometimes a proportionate change improves confidence. But if satisfaction always moves to the next line, photograph, treatment or comparison, the pursuit can consume rather than enlarge life. Ageing is not a personal failure, and an industry that profits from anxiety has little incentive to declare you finished.
Pause when appearance worries dominate the day, mirrors are repeatedly checked or avoided, reassurance never lasts, normal social life shrinks, or another procedure feels urgently necessary. Body dysmorphic disorder is not vanity; it is a treatable mental-health condition. A good clinician should ask what you expect a procedure to change beyond your appearance and should be willing to advise against it.
Recognising body dysmorphic disorderPrimary reading
Follow the evidence, not the personality
US National Institute on AgingResearch and healthy-ageing guidance
ClinicalTrials.govRegistered interventional studies
Dasatinib + quercetin pilotNine-person open-label senolytic study
TA-65 meta-analysisTelomere change without proven functional benefit
FDA supplement warningHidden hormones and safety risks
WHO ageing and healthHealthy ageing in real populations
AHA alcohol statementWhy red wine is not prescribed for health
NIA epigenetic clocksWhat biological-age measures can and cannot tell us
FDA anti-ageing productsCosmetics, drugs and device claims
FDA dermal fillersUses, limits and serious risks
WHO ageismHow negative ageing narratives affect health
Nature Aging longevity analysisWhy radical extension remains implausible today
Alcor pricingCurrent neuro and whole-body arrangements
Cryonics Institute pricingFees and additional logistics costs
Blueprint protocolThe subject's own current account
WHO palliative careQuality of life, access and health-system effects
OECD end-of-life careOvertreatment, preferences, inequality and funding
Lancet Value of Death CommissionRebalancing medicine, community and dying
1971 primate experimentThe original cephalic-exchange paper
Familial hypercholesterolaemiaNIH genetics, inheritance and cardiovascular risk
NHGRI polygenic risk scoresWhat a multi-variant estimate includes and omits
MedlinePlus longevity geneticsHow much lifespan variation genes may explain
NIA Alzheimer's geneticsRisk variants, rare familial disease and testing
NHGRI Huntington's diseasePredictive testing and careful counselling
Parkinson's disease geneticsFamilial genes and complex sporadic risk
Telomere biology disordersTelomerase, shelterin and short-telomere disease
FDA Casgevy approvalApproved CRISPR-edited stem-cell therapy
In-vivo PCSK9 base editingEarly-phase investigational cardiovascular editing
NIA artificial intelligenceAI, multi-omics and exceptional longevity research
UK Biobank whole genomesRare, structural and non-coding variation at scale
NIA epigenetics of ageingMethylation clocks, mechanisms and limitations
Partial reprogramming reviewCellular identity, rejuvenation and tumour risk
NIA mitochondria and ageingEnergy, mtDNA and neurodegeneration
NIA cell biology programmeRNA, autophagy, proteostasis and cellular structure
NIA inflammaging workshopImmune dysregulation, markers and intervention research
CDC immune healthAgeing, vaccination, movement and nutrition
CDC altered immunocompetenceWhy vaccination advice must be individualised
NIH glymphatic studyHuman evidence for brain waste-clearance channels